IL119989A0 - Pharmaceutical compositions for oral treatment of multiple sclerosis - Google Patents

Pharmaceutical compositions for oral treatment of multiple sclerosis

Info

Publication number
IL119989A0
IL119989A0 IL11998997A IL11998997A IL119989A0 IL 119989 A0 IL119989 A0 IL 119989A0 IL 11998997 A IL11998997 A IL 11998997A IL 11998997 A IL11998997 A IL 11998997A IL 119989 A0 IL119989 A0 IL 119989A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
multiple sclerosis
oral treatment
treatment
oral
Prior art date
Application number
IL11998997A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL11998997A priority Critical patent/IL119989A0/xx
Publication of IL119989A0 publication Critical patent/IL119989A0/xx
Priority to EA199900621A priority patent/EA003128B1/ru
Priority to ZA9800214A priority patent/ZA98214B/xx
Priority to HU0001917A priority patent/HU226612B1/hu
Priority to KR1019997006278A priority patent/KR20000070058A/ko
Priority to AT98901745T priority patent/ATE356608T1/de
Priority to AU58195/98A priority patent/AU737287B2/en
Priority to JP53110898A priority patent/JP4216342B2/ja
Priority to CNB988031221A priority patent/CN100528222C/zh
Priority to EP98901745A priority patent/EP0975351B1/en
Priority to CZ0243799A priority patent/CZ297983B6/cs
Priority to PCT/US1998/000375 priority patent/WO1998030227A1/en
Priority to IL13082098A priority patent/IL130820A0/xx
Priority to DE69837324T priority patent/DE69837324T2/de
Priority to NZ336690A priority patent/NZ336690A/en
Priority to CA2277365A priority patent/CA2277365C/en
Priority to BRPI9807076A priority patent/BRPI9807076B8/pt
Priority to SK931-99A priority patent/SK284029B6/sk
Priority to US09/341,369 priority patent/US6214791B1/en
Priority to PL334566A priority patent/PL193300B1/pl
Priority to IL130820A priority patent/IL130820A/en
Priority to HK00104810A priority patent/HK1025737A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
IL11998997A 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis IL119989A0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PL334566A PL193300B1 (pl) 1997-01-10 1998-01-12 Zastosowanie octanu glatirameru oraz kompozycja farmaceutyczna
CZ0243799A CZ297983B6 (cs) 1997-01-10 1998-01-12 Entericky potazená farmaceutická kompozice pro perorální podávání pro lécení roztrousené sklerózy
IL13082098A IL130820A0 (en) 1997-01-10 1998-01-12 Pharmaceutical composition for oral treatment of multiple sclerosis
HU0001917A HU226612B1 (en) 1997-01-10 1998-01-12 Use of glatiramer acetate for production of pharmaceutical composition to the treatment of multiple sclerosis
KR1019997006278A KR20000070058A (ko) 1997-01-10 1998-01-12 공중합체-1의 섭취 또는 흡입을 통한 다발성 경화증의 치료
AT98901745T ATE356608T1 (de) 1997-01-10 1998-01-12 Behandlung der multiplen sklerose durch einnahme von copolymer-1
AU58195/98A AU737287B2 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP53110898A JP4216342B2 (ja) 1997-01-10 1998-01-12 コポリマー１の摂取又は吸入を通じての多発性硬化症の治療
CNB988031221A CN100528222C (zh) 1997-01-10 1998-01-12 共聚物-1在制备治疗多发性硬化症的口服固体药物中的用途
EP98901745A EP0975351B1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion of copolymer-1
EA199900621A EA003128B1 (ru) 1997-01-10 1998-01-12 Способ лечения рассеянного склероза и фармацевтический состав, содержащий сополимер-1
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
ZA9800214A ZA98214B (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
DE69837324T DE69837324T2 (de) 1997-01-10 1998-01-12 Behandlung der multiplen sklerose durch einnahme von copolymer-1
NZ336690A NZ336690A (en) 1997-01-10 1998-01-12 Copolymer-1 [glatiramer acetate (trade name Copaxone)] consists of L-glutamic acid, L-alanine, L-tryrosine and L-lysine for treating multiple sclerosis
CA2277365A CA2277365C (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
BRPI9807076A BRPI9807076B8 (pt) 1997-01-10 1998-01-12 "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
SK931-99A SK284029B6 (sk) 1997-01-10 1998-01-12 Farmaceutická kompozícia na liečenie roztrúsenej sklerózy
US09/341,369 US6214791B1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL130820A IL130820A (en) 1997-01-10 1999-07-06 Pharmaceutical preparations for the oral treatment of multiple sclerosis
HK00104810A HK1025737A1 (en) 1997-01-10 2000-08-01 Treatment of multiple sclerosis through ingestion of copolymer-1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
IL119989A0 true IL119989A0 (en) 1997-04-15

Family

ID=11069682

Family Applications (2)

Application Number Title Priority Date Filing Date
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
IL130820A IL130820A (en) 1997-01-10 1999-07-06 Pharmaceutical preparations for the oral treatment of multiple sclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL130820A IL130820A (en) 1997-01-10 1999-07-06 Pharmaceutical preparations for the oral treatment of multiple sclerosis

Country Status (19)

Country Link
EP (1) EP0975351B1 (xx)
JP (1) JP4216342B2 (xx)
KR (1) KR20000070058A (xx)
CN (1) CN100528222C (xx)
AT (1) ATE356608T1 (xx)
AU (1) AU737287B2 (xx)
BR (1) BRPI9807076B8 (xx)
CA (1) CA2277365C (xx)
CZ (1) CZ297983B6 (xx)
DE (1) DE69837324T2 (xx)
EA (1) EA003128B1 (xx)
HK (1) HK1025737A1 (xx)
HU (1) HU226612B1 (xx)
IL (2) IL119989A0 (xx)
NZ (1) NZ336690A (xx)
PL (1) PL193300B1 (xx)
SK (1) SK284029B6 (xx)
WO (1) WO1998030227A1 (xx)
ZA (1) ZA98214B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
AU766498B2 (en) * 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
DE60017733T2 (de) * 1999-06-04 2006-01-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von riluzol zur behandlung multipler sklerose
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
CN1221281C (zh) * 2000-02-18 2005-10-05 耶达研究与开发有限公司 共聚物1的口服、鼻部和肺部用剂型
AU7528001A (en) * 2000-06-05 2001-12-17 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
CA2469393C (en) 2001-12-04 2010-05-25 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
MXPA04008267A (es) 2002-02-25 2004-11-10 Elan Pharm Inc Administracion de agentes para el tratamiento de la inflamacion.
MXPA05007843A (es) * 2003-01-24 2005-10-18 Elan Pharm Inc Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes.
US7560100B2 (en) 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
DK2949335T3 (en) 2009-08-20 2017-07-31 Yeda Res & Dev LOW FREQUENT GLATIRAMER ACETATE THERAPY
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
EP2906719A4 (en) 2012-10-10 2016-11-09 Teva Pharma PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN112649537B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
EP3645029B1 (en) 2017-06-26 2023-01-18 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
ZA98214B (en) 1999-08-11
EP0975351B1 (en) 2007-03-14
DE69837324D1 (de) 2007-04-26
ATE356608T1 (de) 2007-04-15
JP4216342B2 (ja) 2009-01-28
JP2001511121A (ja) 2001-08-07
IL130820A (en) 2007-03-08
PL334566A1 (en) 2000-03-13
SK93199A3 (en) 2000-11-07
HU226612B1 (en) 2009-04-28
NZ336690A (en) 2001-05-25
WO1998030227A1 (en) 1998-07-16
EP0975351A4 (en) 2002-05-15
KR20000070058A (ko) 2000-11-25
CZ243799A3 (cs) 2000-06-14
BR9807076B1 (pt) 2013-10-29
AU5819598A (en) 1998-08-03
CN1249690A (zh) 2000-04-05
EA003128B1 (ru) 2003-02-27
CZ297983B6 (cs) 2007-05-16
HUP0001917A3 (en) 2001-12-28
PL193300B1 (pl) 2007-01-31
HUP0001917A2 (hu) 2000-10-28
CA2277365C (en) 2011-04-12
AU737287B2 (en) 2001-08-16
CN100528222C (zh) 2009-08-19
DE69837324T2 (de) 2007-11-29
EA199900621A1 (ru) 2000-02-28
BRPI9807076B8 (pt) 2021-05-25
SK284029B6 (sk) 2004-08-03
HK1025737A1 (en) 2000-11-24
BR9807076A (pt) 2000-05-02
CA2277365A1 (en) 1998-07-16
EP0975351A1 (en) 2000-02-02

Similar Documents

Publication Publication Date Title
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
IL113812A (en) Copolymer-1 pharmaceutical compositions containing it and its use
GB0129260D0 (en) Pharmaceutical compositions and their uses
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
IL108007A (en) USE OF AN INTERFERON-GAMMA (IFN-gamma) INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
EP0705100A4 (en) THERAPEUTIC SUBSTITUTED GUANIDINES
HU9303357D0 (en) Pharmaceutical composition containing well-defined lipide-systhem
IL141157A0 (en) Salt form of pantoprazole and pharmaceutical compositions containing the same
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
YU79202A (sh) Peptid koji modulira trombopoetinski receptor
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
AU9731198A (en) Histogranin peptide and their analgesic use
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
UA37278C2 (uk) Протикашльова фармацевтична композиція для перорального введення
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
AU6849198A (en) Neurotrypsin
HUP0002236A2 (hu) Oldhatóvá tett szertralinkészítmények és eljárás az előállításukra
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
GB9015774D0 (en) Novel treatment